论文部分内容阅读
脑卒中后降压治疗临床试验（ＰＡＴＳ）是中国高血压联盟与英国牛津大学临床试验中心合作进行的一个研究项目。该大样本多中心临床试验旨在探讨降压治疗是否能够降低脑卒中或一过性脑缺血（ＴＩＡ）发作后的高血压或正常血压者脑卒中和其他并发症的发生与死亡率。研究对象是：ＴＩＡ或脑卒中后未导致严重残疾者，脑卒中急性期（４周）后，血压水平不限，但医生认为双盲治疗对参加者无害，有严重疾病者除外，入选者随机分入吲哒帕胺治疗组（给予吲哒帕胺２．５ｍｇ／ｄ）或安慰剂对照组（相应安慰剂每日１片）。无降压治疗目标血压。比较２组的脑卒中和其他并发症的发生与死亡率。试验于１９９０年正式开始入选病人，共入选５０００例，随访２年。
Post-stroke Antihypertensive Treatment Trial (PATS) is a research project conducted by China Hypertension Union in collaboration with the Clinical Trials Center of Oxford University. This large, multicenter multicenter trial aims to investigate whether antihypertensive therapy can reduce the incidence and mortality of stroke and other complications associated with hypertension or normotensive after stroke or transient ischemic attack (TIA). Subjects were: TIA or those who did not cause severe disability after stroke, blood pressure was not limited after the acute phase of stroke (4 weeks), but doctors considered double-blind treatment harmless to participants, except for those with serious illness Randomized into indapamide treatment group (given indapamide 2.5mg / d) or placebo control group (corresponding placebo daily 1). No antihypertensive treatment of target blood pressure. The incidence of stroke and other complications and mortality were compared between the two groups. The trial began in 1990, selected patients, a total of 5000 cases were selected, followed up for 2 years.